Moderna (NASDAQ:MRNA)
says it’s submitted an Investigational New Drug application to the FDA
for its mRNA vaccine candidate (mRNA-1273) against the novel
coronavirus.
The company has received initial feedback from the
FDA on the design of the planned Phase 2 trial, which is seen beginning
this quarter. The study will evaluate the safety, reactogenicity and
immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.
Source: Press Release
https://seekingalpha.com/news/3564957-moderna-submits-ind-application-for-phase-2-covidminus-19-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.